Mehul Dhinoja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mehul Dhinoja has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Chow
St Bartholomew’s Hospital, Barts Heart Centre , London
3 shared publications - Steffen Ellebaek Petersen
Barts Heart Centre, St. Bartholomew's Hospital, West Smithfield, W Smithfield, London EC1A 7BE, UK
3 shared publications - James W. Malcolmson
Barts Heart Centre West Smithfield London UK
2 shared publications - Nikhil Ahluwalia
St Bartholomew’s Hospital, Barts Heart Centre , London
2 shared publications - Richard John Schilling
Electrophysiology Department, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
2 shared publications - Ross J. Hunter
St Bartholomew’s Hospital, Barts Heart Centre , London
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (10)
Classic case report: concomitant pulsed field ablation, cavotricuspid isthmus ablation and percutaneous left atrial appendage occlusion in a patient with prior intracranial haemorrhage
Background: Concomitant atrial fibrillation (AF) ablation and percutaneous left atrial appendage occlusion (pLAAO) offers single-procedure rhythm control and stroke prevention in patients unable to tolerate long-term oral anticoagulation. Patients with prior intracranial haemorrhage (ICH) from suspected cerebral amyloid angiopathy (CAA) have among the strongest contraindications to anticoagulation yet are absent from randomized trials of concomitant procedures, and combining pulsed field ablation (PFA) with pLAAO introduces energy-specific considerations. Case Summary: A 66-year-old woman with persistent AF, cavotricuspid isthmus–dependent atrial flutter and a CHA2DS2-VA score of 3 had been off anticoagulation for 2 years after an ICH. Brain magnetic resonance imaging showed microhaemorrhages and siderosis suggestive of CAA. Through a single transseptal puncture, four-vein PFA was performed first to avoid electrical interaction with the nitinol pLAAO frame, followed by WATCHMAN FLX deployment under transoesophageal echocardiographic and computed tomography (CT)–fluoroscopy guidance and radiofrequency cavotricuspid isthmus ablation. She received edoxaban without aspirin for three months. Cardiac CT then confirmed device seal without device-related thrombus, and all antithrombotic therapy was withdrawn. Discussion: Randomized trials show that anticoagulation after ICH prevents ischaemic stroke at the cost of a marked increase in recurrent haemorrhage, and lobar or CAA-related haemorrhage carries the least favourable balance. Concomitant ablation and pLAAO delivers rhythm control and stroke prevention with one transseptal access and one time-limited exposure to anticoagulation. Combining PFA with pLAAO requires sizing the occluder before ablation, because PFA induces acute pulmonary ridge oedema, and completing pulmonary vein isolation before deployment to avoid arcing against the nitinol frame.
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (10)
Open AccessClassic case report: concomitant pulsed field ablation, cavotricuspid isthmus ablation and percutaneous left atrial appendage occlusion in a patient with prior intracranial haemorrhage
Background: Concomitant atrial fibrillation (AF) ablation and percutaneous left atrial appendage occlusion (pLAAO) offers single-procedure rhythm control and stroke prevention in patients unable to tolerate long-term oral anticoagulation. Patients with prior intracranial haemorrhage (ICH) from suspected cerebral amyloid angiopathy (CAA) have among the strongest contraindications to anticoagulation yet are absent from randomized trials of concomitant procedures, and combining pulsed field ablation (PFA) with pLAAO introduces energy-specific considerations. Case Summary: A 66-year-old woman with persistent AF, cavotricuspid isthmus–dependent atrial flutter and a CHA2DS2-VA score of 3 had been off anticoagulation for 2 years after an ICH. Brain magnetic resonance imaging showed microhaemorrhages and siderosis suggestive of CAA. Through a single transseptal puncture, four-vein PFA was performed first to avoid electrical interaction with the nitinol pLAAO frame, followed by WATCHMAN FLX deployment under transoesophageal echocardiographic and computed tomography (CT)–fluoroscopy guidance and radiofrequency cavotricuspid isthmus ablation. She received edoxaban without aspirin for three months. Cardiac CT then confirmed device seal without device-related thrombus, and all antithrombotic therapy was withdrawn. Discussion: Randomized trials show that anticoagulation after ICH prevents ischaemic stroke at the cost of a marked increase in recurrent haemorrhage, and lobar or CAA-related haemorrhage carries the least favourable balance. Concomitant ablation and pLAAO delivers rhythm control and stroke prevention with one transseptal access and one time-limited exposure to anticoagulation. Combining PFA with pLAAO requires sizing the occluder before ablation, because PFA induces acute pulmonary ridge oedema, and completing pulmonary vein isolation before deployment to avoid arcing against the nitinol frame.
- Open Access
- 6 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (5)
Improvement in cardiovascular function after atrial fibrillation ablation in heart failure: association with ECG and echocardiographic variables
- 6 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (5)
Open AccessImprovement in cardiovascular function after atrial fibrillation ablation in heart failure: association with ECG and echocardiographic variables
- Open Access
- 27 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002955
Characterisation of patients who develop atrial fibrillation-induced cardiomyopathy
Introduction: Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ventricular ejection fraction (LVEF) in sinus rhythm. It is unclear why some patients develop AIC. Hypothesis: Patients with AIC have a subtle cardiomyopathic process that precedes their AF-mediated LVEF reduction. Detailed assessment of cardiac function after successful catheter ablation will reveal this. Objective: To evaluate the utility of measures to identify cardiomyopathic features that persist after LVEF normalisation in AIC. Methods: Patients with rate-controlled persistent AF and LVEF<50% undergoing catheter ablation (CA) were prospectively evaluated using echocardiography, cardio-pulmonary exercise testing and serum N-terminal pro b-type natriuretic peptide (NT-proBNP) at baseline and 6 months after CA. Participants with AIC, (LVEF recovery (≥50%) and no other cause for cardiac dysfunction) were evaluated using left ventricular (LV) longitudinal strain and left atrial (LA) reservoir strain (LARS). Changes in peak oxygen consumption and the minute ventilation/carbon dioxide production slope were measured as markers of functional capacity and ventilatory inefficiency. A control group of patients with persistent AF with preserved LVEF were also enrolled. Results: 34/41 (82.9%) participants recovered LVEF in sinus rhythm; defined as AIC. NT-proBNP levels were elevated in 18 (52.9%), and 16 reported ongoing heart failure (HF) symptoms. 10 (29.4%) had no improvement in functional capacity, and seven (20.6%) showed persistent ventilatory inefficiency. 20 (58.8%) had impaired global LV longitudinal strain with a relative apical sparing pattern. Nine (26.5%) had impaired LARS. There was an overlap of these abnormalities. 32 (94.1%) demonstrated at least one, 17 (50.0%) having no cardiovascular risk factors. Patients with preserved LVEF during persistent AF had similar demographics but a lower burden of short R-R intervals (<660 ms) on Holter monitoring. Discussion: Abnormal structural, metabolic and HF biomarkers are seen in patients with AIC in sinus rhythm. These features may represent a precedent subtle cardiomyopathic process predisposing them to left ventricular systolic dysfunction in AF. Trial registration number: NCT04987723.
- 27 November 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002955
Open AccessCharacterisation of patients who develop atrial fibrillation-induced cardiomyopathy
Introduction: Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ventricular ejection fraction (LVEF) in sinus rhythm. It is unclear why some patients develop AIC. Hypothesis: Patients with AIC have a subtle cardiomyopathic process that precedes their AF-mediated LVEF reduction. Detailed assessment of cardiac function after successful catheter ablation will reveal this. Objective: To evaluate the utility of measures to identify cardiomyopathic features that persist after LVEF normalisation in AIC. Methods: Patients with rate-controlled persistent AF and LVEF<50% undergoing catheter ablation (CA) were prospectively evaluated using echocardiography, cardio-pulmonary exercise testing and serum N-terminal pro b-type natriuretic peptide (NT-proBNP) at baseline and 6 months after CA. Participants with AIC, (LVEF recovery (≥50%) and no other cause for cardiac dysfunction) were evaluated using left ventricular (LV) longitudinal strain and left atrial (LA) reservoir strain (LARS). Changes in peak oxygen consumption and the minute ventilation/carbon dioxide production slope were measured as markers of functional capacity and ventilatory inefficiency. A control group of patients with persistent AF with preserved LVEF were also enrolled. Results: 34/41 (82.9%) participants recovered LVEF in sinus rhythm; defined as AIC. NT-proBNP levels were elevated in 18 (52.9%), and 16 reported ongoing heart failure (HF) symptoms. 10 (29.4%) had no improvement in functional capacity, and seven (20.6%) showed persistent ventilatory inefficiency. 20 (58.8%) had impaired global LV longitudinal strain with a relative apical sparing pattern. Nine (26.5%) had impaired LARS. There was an overlap of these abnormalities. 32 (94.1%) demonstrated at least one, 17 (50.0%) having no cardiovascular risk factors. Patients with preserved LVEF during persistent AF had similar demographics but a lower burden of short R-R intervals (<660 ms) on Holter monitoring. Discussion: Abnormal structural, metabolic and HF biomarkers are seen in patients with AIC in sinus rhythm. These features may represent a precedent subtle cardiomyopathic process predisposing them to left ventricular systolic dysfunction in AF. Trial registration number: NCT04987723.
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (7) , e012570
Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing
BACKGROUND: Patients with refractory, symptomatic left ventricular (LV) mid-cavity obstructive (LVMCO) hypertrophic cardiomyopathy have few therapeutic options. Right ventricular pacing is associated with modest hemodynamic and symptomatic improvement, and LV pacing pilot data suggest therapeutic potential. We hypothesized that site-specific pacing would reduce LVMCO gradients and improve symptoms. METHODS: Patients with symptomatic-drug-refractory LVMCO were recruited for a randomized, blinded trial of personalized prescription of pacing (PPoP). Multiple LV and apical right ventricular pacing sites were assessed during an invasive hemodynamic study of multisite pacing. Patient-specific pacing-site and atrioventricular delays, defining PPoP, were selected on the basis of LVMCO gradient reduction and acceptable pacing parameters. Patients were randomized to 6 months of active PPoP or backup pacing in a crossover design. The primary outcome examined invasive gradient change with best-site pacing. Secondary outcomes assessed quality of life and exercise following randomization to PPoP. RESULTS: A total of 17 patients were recruited; 16 of whom met primary end points. Baseline New York Heart Association was 3±0.6, despite optimal medical therapy. Hemodynamic effects were assessed during pacing at the right ventricular apex and at a mean of 8 LV sites. The gradients in all 16 patients fell with pacing, with maximum gradient reduction achieved via LV pacing in 14 (88%) patients and right ventricular apex in 2. The mean baseline gradient of 80±29 mm Hg fell to 31±21 mm Hg with best-site pacing, a 60% reduction ( P P =0.018); other outcome measures also indicated benefit with PPoP. CONCLUSIONS: In a randomized placebo-controlled trial, PPoP reduces obstruction and improves exercise performance in severely symptomatic patients with LVMCO. REGISTRATION: URL: https://clinicaltrials.gov/study ; Unique Identifier: NCT03450252.
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (7) , e012570
Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing
BACKGROUND: Patients with refractory, symptomatic left ventricular (LV) mid-cavity obstructive (LVMCO) hypertrophic cardiomyopathy have few therapeutic options. Right ventricular pacing is associated with modest hemodynamic and symptomatic improvement, and LV pacing pilot data suggest therapeutic potential. We hypothesized that site-specific pacing would reduce LVMCO gradients and improve symptoms. METHODS: Patients with symptomatic-drug-refractory LVMCO were recruited for a randomized, blinded trial of personalized prescription of pacing (PPoP). Multiple LV and apical right ventricular pacing sites were assessed during an invasive hemodynamic study of multisite pacing. Patient-specific pacing-site and atrioventricular delays, defining PPoP, were selected on the basis of LVMCO gradient reduction and acceptable pacing parameters. Patients were randomized to 6 months of active PPoP or backup pacing in a crossover design. The primary outcome examined invasive gradient change with best-site pacing. Secondary outcomes assessed quality of life and exercise following randomization to PPoP. RESULTS: A total of 17 patients were recruited; 16 of whom met primary end points. Baseline New York Heart Association was 3±0.6, despite optimal medical therapy. Hemodynamic effects were assessed during pacing at the right ventricular apex and at a mean of 8 LV sites. The gradients in all 16 patients fell with pacing, with maximum gradient reduction achieved via LV pacing in 14 (88%) patients and right ventricular apex in 2. The mean baseline gradient of 80±29 mm Hg fell to 31±21 mm Hg with best-site pacing, a 60% reduction ( P P =0.018); other outcome measures also indicated benefit with PPoP. CONCLUSIONS: In a randomized placebo-controlled trial, PPoP reduces obstruction and improves exercise performance in severely symptomatic patients with LVMCO. REGISTRATION: URL: https://clinicaltrials.gov/study ; Unique Identifier: NCT03450252.
- Open Access
- 4 June 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (7)
Near-field detection and peak frequency metric for substrate and activation mapping of ventricular tachycardias in two- and three-dimensional circuits
Successful ventricular arrhythmia (VA) ablation requires identification of functionally critical sites during contact mapping. Estimation of the peak frequency (PF) component of the electrogram (EGM) may improve correct near-field (NF) annotation to identify circuit segments on the mapped surface. In turn, assessment of NF and far-field (FF) EGMs may delineate the three-dimensional path of a ventricular tachycardia (VT) circuit. A proprietary NF detection algorithm was applied retrospectively to scar-related re-entry VT maps and compared with manually reviewed maps employing first deflection (FDcorr) for VT activation maps and last deflection (LD) for substrate maps. Ventricular tachycardia isthmus location and characteristics mapped with FDcorr vs. NF were compared. Omnipolar low-voltage areas, late activating areas, and deceleration zones (DZ) in LD vs. NF substrate maps were compared. On substrate maps, PF estimation was compared between isthmus and bystander sites. Activation mapping with entrainment and/or VT termination with radiofrequency (RF) ablation confirmed critical sites. Eighteen patients with high-density VT activation and substrate maps (55.6% ischaemic) were included. Near-field detection correctly located critical parts of the circuit in 77.7% of the cases compared with manually reviewed VT maps as reference. In substrate maps, NF detection identified deceleration zones in 88.8% of cases, which overlapped with FDcorr VT isthmus in 72.2% compared with 83.3% overlap of DZ assessed by LD. Applied to substrate maps, PF as a stand-alone feature did not differentiate VT isthmus sites from low-voltage bystander sites. Omnipolar voltage was significantly higher at isthmus sites with longer EGM durations compared with low-voltage bystander sites. The NF algorithm may enable rapid high-density activation mapping of VT circuits in the NF of the mapped surface. Integrated assessment and combined analysis of NF and FF EGM-components could support characterization of three-dimensional VT circuits with intramural segments. For scar-related substrate mapping, PF as a stand-alone EGM feature did not enable the differentiation of functionally critical sites of the dominant VT from low-voltage bystander sites in this cohort. Left top: LAT emphasis maps in VT activation mapping—Exemplary VT LAT maps with LAT-on-LAT emphasis in a RV VT and LV VT to highlight diastolic potentials. Left bottom: Example of left ventricular substrate map in a patient with extensive chronic anterior myocardial infarct (left, grey < 0.1 mV, purple > 1.5 mV) with emphasis on high-frequency EGMs (middle, emphasizing EGMs with >250 Hz) and visualization of peak frequency values (right, with nominal thresholds of EnSite X: grey < 200 Hz, white > 250 Hz). Right: Schematic illustration of how integration of NF and FF information may allow to distinguish two- and three-dimensional VT circuits and estimate the three-dimensional path of the VTCC. Yet, important confounders for using NF and peak frequency in ventricular mapping exist and need to be considered. 2D, two-dimensional; 3D, three-dimensional; EGM, electrogram; ICM, ischaemic cardiomyopathy; FF, far field; LV, left ventricle; NF, near field; RV, right ventricle; VT, ventricular tachycardia.
- 4 June 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (7)
Open AccessNear-field detection and peak frequency metric for substrate and activation mapping of ventricular tachycardias in two- and three-dimensional circuits
Successful ventricular arrhythmia (VA) ablation requires identification of functionally critical sites during contact mapping. Estimation of the peak frequency (PF) component of the electrogram (EGM) may improve correct near-field (NF) annotation to identify circuit segments on the mapped surface. In turn, assessment of NF and far-field (FF) EGMs may delineate the three-dimensional path of a ventricular tachycardia (VT) circuit. A proprietary NF detection algorithm was applied retrospectively to scar-related re-entry VT maps and compared with manually reviewed maps employing first deflection (FDcorr) for VT activation maps and last deflection (LD) for substrate maps. Ventricular tachycardia isthmus location and characteristics mapped with FDcorr vs. NF were compared. Omnipolar low-voltage areas, late activating areas, and deceleration zones (DZ) in LD vs. NF substrate maps were compared. On substrate maps, PF estimation was compared between isthmus and bystander sites. Activation mapping with entrainment and/or VT termination with radiofrequency (RF) ablation confirmed critical sites. Eighteen patients with high-density VT activation and substrate maps (55.6% ischaemic) were included. Near-field detection correctly located critical parts of the circuit in 77.7% of the cases compared with manually reviewed VT maps as reference. In substrate maps, NF detection identified deceleration zones in 88.8% of cases, which overlapped with FDcorr VT isthmus in 72.2% compared with 83.3% overlap of DZ assessed by LD. Applied to substrate maps, PF as a stand-alone feature did not differentiate VT isthmus sites from low-voltage bystander sites. Omnipolar voltage was significantly higher at isthmus sites with longer EGM durations compared with low-voltage bystander sites. The NF algorithm may enable rapid high-density activation mapping of VT circuits in the NF of the mapped surface. Integrated assessment and combined analysis of NF and FF EGM-components could support characterization of three-dimensional VT circuits with intramural segments. For scar-related substrate mapping, PF as a stand-alone EGM feature did not enable the differentiation of functionally critical sites of the dominant VT from low-voltage bystander sites in this cohort. Left top: LAT emphasis maps in VT activation mapping—Exemplary VT LAT maps with LAT-on-LAT emphasis in a RV VT and LV VT to highlight diastolic potentials. Left bottom: Example of left ventricular substrate map in a patient with extensive chronic anterior myocardial infarct (left, grey < 0.1 mV, purple > 1.5 mV) with emphasis on high-frequency EGMs (middle, emphasizing EGMs with >250 Hz) and visualization of peak frequency values (right, with nominal thresholds of EnSite X: grey < 200 Hz, white > 250 Hz). Right: Schematic illustration of how integration of NF and FF information may allow to distinguish two- and three-dimensional VT circuits and estimate the three-dimensional path of the VTCC. Yet, important confounders for using NF and peak frequency in ventricular mapping exist and need to be considered. 2D, two-dimensional; 3D, three-dimensional; EGM, electrogram; ICM, ischaemic cardiomyopathy; FF, far field; LV, left ventricle; NF, near field; RV, right ventricle; VT, ventricular tachycardia.
- Open Access
- 2 August 2022
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 16
Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
Introduction: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment, reduced LVMCO and improved refractory symptoms. Methods: Between December 2008 and December 2017, 16 HCM patients with severe refractory symptoms and LVMCO underwent device implantation with haemodynamic pacing study to assess the effect on invasively defined LVMCO gradients. The effect on the gradient of atrioventricular (AV) synchronous pacing from sites including right ventricular (RV) apex and middle cardiac vein (MCV) was retrospectively assessed. Results: Invasive haemodynamic data were available in 14 of 16 patients. Mean pre-treatment intracavitary gradient was 77 ± 22 mmHg (in sinus rhythm) versus 21 ± 21 mmHg during pacing from optimal ventricular site (95% CI: −70.86 to −40.57, p < 0.0001). Optimal pacing site was distal MCV in 12/16 (86%), RV apex in 1/16 and via epicardial LV lead in 1/16. Pre-pacing Doppler-derived gradients were significantly higher than at follow-up (47 ± 15 versus 24 ± 16 mmHg, 95% CI: −37.19 to −13.73, p < 0.001). Median baseline NYHA class was 3, which had improved by ⩾1 NYHA class in 13 of 16 patients at 1-year post-procedure ( p < 0.001). The mean follow-up duration was 4.6 ± 2.7 years with the following outcomes: 8/16 (50%) had continued symptomatic improvement, 4/16 had symptomatic decline and 4/16 died. Contributors to symptomatic decline included chronic atrial fibrillation (AF) ( n = 5), phrenic nerve stimulation ( n = 3) and ventricular ectopy ( n = 1). Conclusion: In drug-refractory symptomatic LVMCO, distal ventricular pacing can reduce intracavitary obstruction and may provide long-term symptomatic relief in patients with limited treatment options. A haemodynamic pacing study is an effective strategy for identifying optimal pacing site and configuration.
- 2 August 2022
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 16
Open AccessTherapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
Introduction: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment, reduced LVMCO and improved refractory symptoms. Methods: Between December 2008 and December 2017, 16 HCM patients with severe refractory symptoms and LVMCO underwent device implantation with haemodynamic pacing study to assess the effect on invasively defined LVMCO gradients. The effect on the gradient of atrioventricular (AV) synchronous pacing from sites including right ventricular (RV) apex and middle cardiac vein (MCV) was retrospectively assessed. Results: Invasive haemodynamic data were available in 14 of 16 patients. Mean pre-treatment intracavitary gradient was 77 ± 22 mmHg (in sinus rhythm) versus 21 ± 21 mmHg during pacing from optimal ventricular site (95% CI: −70.86 to −40.57, p < 0.0001). Optimal pacing site was distal MCV in 12/16 (86%), RV apex in 1/16 and via epicardial LV lead in 1/16. Pre-pacing Doppler-derived gradients were significantly higher than at follow-up (47 ± 15 versus 24 ± 16 mmHg, 95% CI: −37.19 to −13.73, p < 0.001). Median baseline NYHA class was 3, which had improved by ⩾1 NYHA class in 13 of 16 patients at 1-year post-procedure ( p < 0.001). The mean follow-up duration was 4.6 ± 2.7 years with the following outcomes: 8/16 (50%) had continued symptomatic improvement, 4/16 had symptomatic decline and 4/16 died. Contributors to symptomatic decline included chronic atrial fibrillation (AF) ( n = 5), phrenic nerve stimulation ( n = 3) and ventricular ectopy ( n = 1). Conclusion: In drug-refractory symptomatic LVMCO, distal ventricular pacing can reduce intracavitary obstruction and may provide long-term symptomatic relief in patients with limited treatment options. A haemodynamic pacing study is an effective strategy for identifying optimal pacing site and configuration.
- Open Access
- 30 July 2022
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 8 (10) , 699-701
The use of a needle’s eye snare to extract a leadless pacemaker in a patient with a persistent bacteremia
- 30 July 2022
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 8 (10) , 699-701
Open AccessThe use of a needle’s eye snare to extract a leadless pacemaker in a patient with a persistent bacteremia